193 related articles for article (PubMed ID: 32540147)
1. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
3. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
6. [Dermato-neuro syndrome during scleromyxedema: efficacy of plasmapheresis and intravenous immunoglobulin].
Charles S; Hainaut E; Cante V; Valette C; Levillain P; Guillet G
Ann Dermatol Venereol; 2014; 141(8-9):523-7. PubMed ID: 25209816
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
8. Dermato-neuro syndrome after COVID-19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins.
Li Y; Wang H; Wang A; Zhao G
J Dermatol; 2024 Jan; 51(1):140-144. PubMed ID: 37830263
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxedema.
Hoffmann JHO; Enk AH
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1449-1467. PubMed ID: 33373143
[TBL] [Abstract][Full Text] [Related]
10. [Dermato-neuro syndrome-an acute and life-threatening complication of scleromyxedema Arndt-Gottron].
Linse KP; Enk A; Hoffmann J
Dermatologie (Heidelb); 2023 Aug; 74(8):618-620. PubMed ID: 37284981
[TBL] [Abstract][Full Text] [Related]
11. Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.
Taha RY; Hasan S; Ibrahim F; Chantran Y; Sabah HE; Sivaraman S; Bozom IA; Sabbagh AA; Garderet L; Omri HE
Medicine (Baltimore); 2020 Jul; 99(27):e20726. PubMed ID: 32629647
[TBL] [Abstract][Full Text] [Related]
12. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature.
Fleming KE; Virmani D; Sutton E; Langley R; Corbin J; Pasternak S; Walsh NM
J Cutan Pathol; 2012 May; 39(5):508-17. PubMed ID: 22515222
[TBL] [Abstract][Full Text] [Related]
13. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
14. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
15. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
16. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
17. Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e213-5. PubMed ID: 25065780
[No Abstract] [Full Text] [Related]
18. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
19. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
20. Scleromyxedema with dermato-neuro syndrome.
Gonzalez J; Palangio M; Schwartz J; Klainer AS; Bisaccia E
J Am Acad Dermatol; 2000 May; 42(5 Pt 2):927-8. PubMed ID: 10767707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
